Bowel ulceration following tocilizumab administration in a COVID-19 patient.
BMJ Open Gastroenterol
; 7(1)2020 08.
Article
in English
| MEDLINE | ID: covidwho-724113
ABSTRACT
Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestinal side effects seen when used in the context of COVID-19 are unknown. We present a case of COVID-19 CRS in which acute terminal ileum and perforated caecal ulceration evolved after tocilizumab exposure. We raise awareness of a possible causal relationship between even a single dose of tocilizumab and gut ulceration in patients with COVID-19. Any such drug enteropathy relationship requires watchful monitoring during upcoming trials of tocilizumab in patients with COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Colitis, Ulcerative
/
Coronavirus Infections
/
Antibodies, Monoclonal, Humanized
/
Betacoronavirus
Type of study:
Case report
/
Diagnostic study
/
Observational study
Topics:
Vaccines
Limits:
Adult
/
Humans
/
Male
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
Bmjgast-2020-000484
Similar
MEDLINE
...
LILACS
LIS